Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity

Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin

“…It was obtained by transplanting the complementarity determining regions (CDR) of the murine IgG2a monoclonal ior egf/r3, to a human framework assisted by computer modeling. 5 The parental murine monoclonal ior egf/ r3 was generated by fusing the murine myeloma cells SP2/Ag14 with splenocytes from Balb/c mice immunized with a purified human placenta fraction enriched in EGFR and not with EGFR purified from cultured cells. 6 Studies have shown nimotuzumab mediates anti-tumour effects by its capacity to inhibit proliferation, survival and angiogenesis.…”

Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies

“…The humanised anti-EGFR mAb nimotuzumab was generated at the Centre of Molecular Immunology (Mateo et al, 1997). All the primary and secondary antibodies were Revised 15 January 2009; accepted 22 January 2009 purchased from commercial sources listed as follows: rabbit polyclonal EGFR antibody to total EGFR (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), mouse monoclonal anti-phosphotyrosine antibody (BD Pharmingen, San Diego, CA, USA), mouse monoclonal ERK1/2 antibody to total ERK1/2 (BD Pharmingen), rabbit polyclonal phospho-p44/42 MAPK (Thr202/Tyr204) antibody to activated ERK1/2 (BD Pharmingen), mouse monoclonal antibody MIB-1 to Ki-67 (DakoCytomation, Carpinteria, CA, USA), rat monoclonal anti CD31/PECAM-1 antibody (BD Pharmingen), biotin-conjugated mouse monoclonal antibody to CD133/1 (AC133) (Miltenyi Biotec, Cologne, Germany).…”

Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner

“…The neutralizing anti-human EGFR monoclonal antibody C225 (Fan et al, 1993;Goldstein et al, 1995) and the monoclonal antibody hR3, directed against the same target (Mateo et al, 1997) were provided by ImClone Systems (New York, NY, USA) and the Centre of Molecular Immunology (CIM) (Havana, Cuba), respectively. The anti-TGF-a monoclonal antibody Ab-3 was purchased from Calbiochem (Cambridge, MA, USA).…”